Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)

Executive Summary

• Cannabix Technologies Inc. announced the commencement of a phased commercial rollout of its Marijuana Breath Test (MBT) system to select customers across multiple industries.
• The MBT provides non‑invasive detection of recent delta‑9 THC use in breath within ~4 hours, addressing a market need for timely cannabis impairment testing.
• An independent peer‑reviewed study in the Journal of Analytical Toxicology validates the technology; the company has established manufacturing, QA/QC, FCC compliance, and partnership processes to support scale‑up.

Key Details

• Rollout Phase: Delivery of MBT handheld Breath Collection Units (BCU) and disposable Breath Cartridges to initial commercial customers; subsequent production scale‑up planned.
• Technology Capability: Detects delta‑9 THC in breath at concentrations > 5 pg/L within approximately 4 hours of consumption, distinguishing recent use from historical exposure.
• Scientific Validation: March 2026 peer‑reviewed article (“Simultaneous Analysis of Δ9‑THC, Δ8‑THC, CBD, and CBN in Breath Aerosols…”) confirms detection limits and methodology.
• Regulatory & Compliance Milestones:
• BCU passed FCC electronic emissions testing.
• Validation package prepared by Omega Laboratories; integration into Omega’s chain‑of‑custody and LIMS reporting workflows.
• Manufacturing Readiness: Established SOPs, QA/QC processes, and partnerships for hardware production; ongoing logistics planning and end‑user training material development.
• Revenue Model: Recurring revenue from disposable Breath Cartridges used per test; BCU sold as reusable hardware platform.
• Partner Ecosystem: Strategic partnership with Omega Laboratories (global forensic drug‑testing leader) for laboratory‑developed test method and certification support.
• Pre‑Launch Marketing: Collaborative marketing initiatives conducted with Omega (Ohio) and AlcoPro (Knoxville, TN).
• Forward‑Looking Statements: Company projects continued customer adoption, manufacturing scale‑up, and additional commercial agreements; acknowledges typical risks associated with product commercialization and regulatory environments.

Notable Quotes

“The Marijuana Breath Test fills a critical gap and delivers new technology… providing a complete, non‑invasive solution for detecting recent cannabis use.” – Rav Mlait, CEO, Cannabix Technologies Inc.